Kalos Management’s GSK GSK Stock Holding History

Kalos Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-160	Closed	-$5.69K	–	230
2023 Q1	$5.69K	Buy	+160	New	+$5.6K	0.01%	265
2015 Q4	–	Hold	0	–	–	–	238

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kalos Management's GSK Position: Q2 2023 in Review

Kalos Management sold out of GSK (GSK) in Q2 2023, closing a stake of 160 shares — an estimated $5.69K sold.

Kalos Management first reported a position in GSK in Q1 2023 and held it in 1 quarter. The position peaked at $5.69K in Q1 2023. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Kalos Management reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Kalos Management sold 160 GSK shares in Q2 2023, an estimated $5.69K.
Kalos Management first reported a position in GSK in Q1 2023 and held it in 1 quarter.
Kalos Management's GSK position peaked at $5.69K in Q1 2023.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Kalos Management's 13F filing for Q2 2023, filed 9 Aug 2023.